

DAFTAR ISI

HALAMAN JUDUL.....	i
HALAMAN PENGESAHAN.....	ii
PERNYATAAN BEBAS PLAGIASI	iii
PRAKATA.....	iv
DAFTAR ISI.....	vi
DAFTAR TABEL.....	viii
DAFTAR GAMBAR	ix
DAFTAR LAMPIRAN	x
ARTI LAMBANG DAN SINGKATAN	xi
INTISARI.....	xii
ABSTRACT	xiv
BAB I. PENDAHULUAN	1
I.1 Latar Belakang.....	1
I.2 Perumusan Masalah	5
I.3 Tujuan Penelitian	6
I.4 Keaslian Penelitian	7
I.5 Manfaat Penelitian	8
BAB II. TINJAUAN PUSTAKA.....	9
II.1 Tinjauan Pustaka	9
II.1.1 Gagal Ginjal Kronis dan Fibrosis Ginjal	9
II.1.2 Nefrektomi Subtotal 5/6	13
II.1.3 <i>Transforming Growth Factor-β</i> (TGF-β).....	14
II.1.4 Endothelin-1, ET _A R dan ET _B R.....	17
II.1.5 <i>endothelial Nitric Oxide Synthase</i> (eNOS).....	19
II.1.6 Vitamin D	20
II.2 Landasan Teori	23
II.3 Kerangka Teori.....	26
II.4 Kerangka Konsep	27
II.5 Hipotesis	27
BAB III. METODE PENELITIAN.....	29
III.1 Jenis dan Rancangan Penelitian	29
III.2 Variabel Penelitian	29
III.3 Definisi Operasional	29
III.4 Bahan dan Alat Penelitian.....	31
III.4.1 Bahan Penelitian.....	31
III.4.2. Alat Penelitian.....	33
III.5 Jalannya Penelitian.....	33

III.5.1 Tempat Penelitian.....	33
III.5.2 Subjek Penelitian.....	34
III.5.3 Perlakuan Hewan Coba dan Pemberian Vitamin D	34
III.5.4 Prosedur Nefrektomi Subtotal 5/6.....	36
III.5.5 Terminasi Hewan Coba.....	37
III.5.6 Ekstraksi RNA	38
III.5.7 Pembuatan cDNA (<i>complementary DNA</i>).....	39
III.5.8 <i>Reverse Transcriptase</i> PCR (RT-PCR).....	39
III.5.9 Elektroforesis	40
III.5.10 Pemeriksaan <i>immunohistochemistry</i> antibodi anti α -SMA dan PDGFR β	40
III.5.11 Pemeriksaan Ekspresi Protein α -SMA dan PDGFR β	41
III.5.12 Pewarnaan Sirius Red	41
III.5.13 Pemeriksaan Fraksi Area Fibrosis.....	41
III.6 Analisis Hasil	42
BAB IV. HASIL PENELITIAN DAN PEMBAHASAN	43
IV.1 Hasil Penelitian	43
IV.1 Karakteristik Hewan Coba Model Gagal Ginjal Kronis dengan Nefrektomi Subtotal 5/6.....	43
IV.2 Fraksi Area Fibrosis.....	44
IV.3 Ekspresi protein α -SMA dan PDGFR β	46
IV.4 Ekspresi TGF- β	48
IV.5 Ekspresi prepro-ET-1	50
IV.6 Ekspresi ET _A R	51
IV.7 Ekspresi ET _B R	53
IV.8 Ekspresi eNOS	54
IV.2 Pembahasan.....	56
BAB V. KESIMPULAN, SARAN DAN RINGKASAN	69
V.1 Kesimpulan	69
V.2 Saran.....	70
V.3 Ringkasan	70
DAFTAR PUSTAKA	90
LAMPIRAN	99

DAFTAR TABEL

Tabel 1. Jumlah Tikus pada Akhir Perlakuan	43
--	----

DAFTAR GAMBAR

Gambar 1. Empat fase fibrosis ginjal.....	11
Gambar 2. Jalur sinyal <i>canonical</i> dan <i>non-canonical</i> TGF- β	16
Gambar 3. Produksi ET-1 dan efek kerjanya.....	18
Gambar 4. Kerangka Teori.....	26
Gambar 5. Kerangka konsep penelitian yang diajukan.....	27
Gambar 6. <i>Timeline</i> Penelitian.....	35
Gambar 7. Diagram Penelitian.....	36
Gambar 8. Gambaran histologis ginjal pewarnaan Sirius Red	45
Gambar 9. Diagram batang rerata fraksi area fibrosis	46
Gambar 10. Gambaran histologis ginjal pewarnaan imunohistokimia α -SMA....	47
Gambar 11. Gambaran histologis ginjal pewarnaan imunohistokima PDGFR β ..	48
Gambar 12. Hasil elektroforesis TGF- β 1 dan GAPDH	49
Gambar 13. Diagram batang rerata ekspresi TGF- β 1/GAPDH.....	50
Gambar 14. Hasil elektroforesis prepro-ET-1 dan GAPDH	50
Gambar 15. Diagram batang rerata ekspresi prepro-ET-1/GAPDH	51
Gambar 16. Hasil elektroforesis ET _A R dan GAPDH.....	52
Gambar 17. Diagram batang rerata ekspresi ET _A R/GAPDH.....	52
Gambar 18. Hasil elektroforesis ET _B R dan GAPDH.....	53
Gambar 19. Diagram batang rerata ekspresi ET _B R /GAPDH.....	54
Gambar 20. Hasil elektroforesis eNOS dan GAPDH	55
Gambar 21. Diagram batang rerata ekspresi eNOS/GAPDH	55

DAFTAR LAMPIRAN

Lampiran 1. Surat Keterangan Kelaikan Etik	99
Lampiran 2. Uji Normalitas dan Homogenitas Data.....	100
Lampiran 3. Hasil Uji Parametrik (One-Way ANOVA dan Post Hoc LSD) atau Non Parametrik (Kruskal Wallis H dan Mann-Whitney U)	102

ARTI LAMBANG DAN SINGKATAN

1,25(OH) ₂ D ₃	Kalsitriol
25(OH)D ₃	Kalsifediol
BMP	<i>Bone Morphogenetic Proteins</i>
eNOS	<i>endothelial Nitric Oxide Synthase</i>
ET-1	<i>Endothelin-1</i>
ET _A R	Reseptor ET _A
ET _B R	Reseptor ET _B
ERK	<i>Extracellular-signal Regulated Kinase</i>
FGF-23	<i>Fibroblast Growth Factor-23</i>
GAPDH	<i>Glyceraldehyde-3-phosphate dehydrogenase</i>
MAPK	<i>Mitogen Activated Protein Kinase</i>
MEK	<i>MAPK/ERK Kinase</i>
MMP	<i>Matrix metalloproteinase</i>
mRNA	<i>Messenger Ribonucleic Acid</i>
NF-κB	<i>Nuclear Factor kappa B subunit</i>
NO	<i>Nitric oxide</i>
NOS	<i>Nitric oxide synthase</i>
PCNA	<i>Proliferating cellular antigen</i>
PDGFRβ	<i>Platelet-derived growth factor Receptor Beta</i>
PI3K/Akt	<i>Phosphatidylinositol 3-kinase</i>
PPET-1	<i>Prepro-ET-1</i>
RAAS	<i>Renin-Angiotensin Aldosterone System</i>
RT-PCR	<i>Reverse Transcriptase Polymerase Chain Reaction</i>
RXR	Reseptor Asam Retinoat
SD	<i>Sprague-Dawley</i>
SN	Nefrektomi Subtotal 5/6
SO	Sham Operation
TAK1	<i>TGF-β-activated kinase 1</i>
TIMP	<i>Tissue inhibitor of metalloproteinase</i>
TGF-β1	<i>Transforming growth factors beta-1</i>
TβRI	TGF-β reseptor tipe-I
TβRII	TGF-β reseptor tipe-II
UO	<i>Unilateral Ureteral Obstruction</i>
VDR	<i>Vitamin D Receptor</i>
VDRE	<i>Vitamin D Response Elements</i>
VEETKO	<i>Vascular Endothelial Cell-Specific ET-1 Knock Out</i>
WT1	<i>Wilms tumor gene</i>
α-SMA	<i>alpha Smooth Muscle Actin</i>